Last $4.24 USD
Change Today -0.05 / -1.17%
Volume 359.2K
PSDV On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
Frankfurt
OTC US
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

psivida corp (PSDV) Snapshot

Open
$4.25
Previous Close
$4.29
Day High
$4.49
Day Low
$4.17
52 Week High
10/2/13 - $5.60
52 Week Low
10/31/13 - $2.28
Market Cap
124.4M
Average Volume 10 Days
461.8K
EPS TTM
$-2.23
Shares Outstanding
29.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PSIVIDA CORP (PSDV)

psivida corp (PSDV) Related Businessweek News

No Related Businessweek News Found

psivida corp (PSDV) Details

pSivida Corp. develops products to deliver drugs and biologics in the United States and the United Kingdom. The company develops its products based on its Durasert and Tethadur drug delivery technologies focusing on the treatment of chronic diseases of the back of the eye. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company also provides Medidur, an injectable, sustained-release micro-insert designed to treat non-infectious uveitis affecting the posterior segment of the eye, which is in Phase III clinical trial.It has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Enigma Therapeutics Limited; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is headquartered in Watertown, Massachusetts.

24 Employees
Last Reported Date: 09/11/14
Founded in 1987

psivida corp (PSDV) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $728.3K
Principal Financial & Accounting Officer and ...
Total Annual Compensation: $302.7K
Vice President of Corporate Affairs, General ...
Total Annual Compensation: $466.4K
Compensation as of Fiscal Year 2013.

psivida corp (PSDV) Key Developments

pSivida Corp. Names James J. Barry to Board of Directors

pSivida Corp. announced that it has elected James J. Barry to its Board of Directors. Dr. Barry, currently serves as Executive Vice President and Chief Operating Officer of InspireMD. Dr. Barry currently serves on a number of advisory boards including the College of Biomedical Engineering at Yale University, the College of Sciences at University of Massachusetts-Lowell and the Massachusetts Life Science Center.

pSivida Corp. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Fiscal Year Ended June 30, 2014

pSivida Corp. reported unaudited consolidated financial results for the fourth quarter and fiscal year ended June 30, 2014. For the quarter, the company reported net loss of $3,967,000 or $0.14 per basic and diluted share on total revenues of $292,000 against net loss of $3,947,000 or $0.17 per basic and diluted share on total revenues of $492,000 a year ago. Loss from operations was $4,012,000 compared to $3,981,000 a year ago. Loss before income taxes was $4,010,000 compared to $3,979,000 a year ago. Decrease in revenue was predominantly related to collaborative research and development revenue largely resulted from lower amortization of deferred revenue balances. For the year, the company reported net loss of $13,355,000 or $0.49 per basic and diluted share on total revenues of $3,473,000 against net loss of $11,900,000 or $0.52 per basic and diluted share on total revenues of $2,143,000 a year ago. Loss from operations was $13,490,000 compared to $12,031,000 a year ago. Loss before income taxes was $13,485,000 compared to $12,017,000 a year ago. The revenues were primarily attributable to recognition of $1.5 million of consideration from a feasibility study agreement upon resolution of a contingency.

pSivida Corp. to Report Q4, 2014 Results on Sep 09, 2014

pSivida Corp. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Sep 09, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSDV:US $4.24 USD -0.05

PSDV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $168.21 USD -1.76
Regeneron Pharmaceuticals Inc $358.92 USD -3.82
View Industry Companies
 

Industry Analysis

PSDV

Industry Average

Valuation PSDV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.7x
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PSIVIDA CORP, please visit www.psivida.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.